Effects of Ranolazine on Coronary Microvascular Dysfunction in Patients With Hypertrophic Cardiomyopathy

Inclusion Criteria: * Male and female gender (females of childbearing potential must be using highly effective contraceptive precautions such as implants, injectables, combined oral contraceptives, intrauterine devices, sexual abstinence or vasectomised partner); * Females of childbearing potential or within two years from the menopause must have a negative urine pregnancy test; * Patients which fulfill conventional echocardiographic criteria for the diagnosis of HCM: maximum LV wall thickness ≥ 15 mm; * Patients aged \> 18 years and \< 80 years; * Sinus rhythm accepted isolated Supraventricular and Ventricular Premature Beats (VPB); * Absence of severe resting LV outflow tract obstruction (peak gradient ≤ 50 mmHg); * Written informed consent prior to enrolment into the study; Exclusion Criteria: * Females of childbearing potential not using highly effective contraceptive precautions; * Presence of known coronary artery disease (CAD); * Presence of Chronic Obstructive Airways Disease; * Asthma; * Other causes of microvascular dysfunction including long-standing history of arterial hypertension, diabetes, uncontrolled dyslipidemia; * Body mass index \>32 kg/m2; \< 17 kg/m2 * Overt LV systolic dysfunction with end-stage progression (LV-EF \<50%); * Concomitant administration of potent CYP3A4 inhibitors (e.g. itraconazole, ketoconazole, voriconazol, posaconazol, HIV protease inhibitors, clarithromycin, telithromycin, nefazodone); * Patients treated with sotalol, dronedarone, …